Approved the Standalone and Consolidated Audited Financial Results for the quarter
As filed · Outcome of Board Meeting
EarningsMajormateriality 77 out of 100
What happened
FactApproved the Standalone and Consolidated Audited Financial Results for the quarter. Standalone and Consolidated Statement of Assets and Liabilities as at 31st. Standalone and Consolidated Cash Flow Statements for the financial year ended.
Why it matters
CapitSignal interpretationReported results are the point at which prior management commitments become checkable against audited or reviewed numbers.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Debt
WithdrawnEarlierQ1 FY27
gross debt was about -- we are at around INR1,600 crores of gross debt.
NowQ1 FY27
we should see this debt levels moderating.
Change
FactGuidance withdrawn
Implication
CapitSignal interpretationDetected a change between two statements on this topic.confidence 60%
Watch next
Fact- Margin trend against the prior period
- Cash from operations against reported profit
- Whether prior guidance is reaffirmed
- I think about 15-odd percent or so of what I've guided for that the business will grow, and I think we're quit (management committed by FY27)
- Expenditures on artificial intelligence within the healthcare sector are anticipated to attain a value of US$ (management committed by FY30)
Evidence
- Alembic Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.(opens the original filing in a new tab)
- Earlier statement · Q1 FY27
- Latest statement · Q1 FY27
- Earlier statement · Q1 FY27
How CapitSignal classified this
- Reasoning:
- RESULTS base 68; +4 corroborating keywords; +5 quantified amount; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%